INFLUENCE OF LOVASTATIN ON PHARMACOKINETICS AND PHARMACODYNAMICS OF GLIPIZIDE IN HEALTHY AND STREPTOZOTOCIN - INDUCED DIABETIC RATS: INVOLVEMENT OF P-GLYCOPROTEIN INHIBITION
DOI:
https://doi.org/10.22159/ajpcr.2016.v9i5.1191Abstract
This study evaluated the effect of lovastatin (Lov) on the pharmacokinetics and pharmacodynamics of glipizide (Gpz) in healthy and streptozotocininduced
diabetic rats. In single dose study (SDS), blood samples were collected on the 1st day, whereas in multiple dose study on the 15th day at 0-12 hrs. Lov significantly altered the pharmacokinetic parameters at the dose of 15 mg/kg in SDS and multiple dose study. The Cmax of Gpz was increased from 2.97 to 8.38 and 9.87 to 24.58 ng/mL in healthy and diabetic rats, respectively, in multiple dose study. Rat everted sacs were used to study the transport of Gpz in the presence of Lov and verapamil (P-glycoprotein [P-gp] inhibitor). The transport of Gpz from mucosal to the serosal surface was significantly increased from 4.32 to 5.65 and 6.02 μg/mL in the presence of Lov and verapamil, respectively. The interaction between Lov and Gpz is due to P-gp and CYP2C9 inhibition.
Keywords: Diabetes, Dyslipidemia, Glipizide, Lovastatin, P-glycoprotein.
Downloads
References
Vijayaraghavan K. Treatment of dyslipidemia in patients with Type 2 diabetes. Lipids Health Dis 2010;9:144.
Parikh RM, Joshi SR, Menon PS, Shah NS. Prevalence and pattern of diabetic dyslipidemia in Indian Type 2 diabetic patients. Diabetes Metab Syndr Clin Res Rev 2010;4(1):10-2.
Blumenthal D, Buxton I, Parker K. Goodman & Gilman’s. Manual of Pharmacology and Therapeutics. New York: McGraw- Hill; 2007. p. 611.
Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994;16(3):366-85.
Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348(9034):1079-82.
Tobert JA. New developments in lipid-lowering therapy: The role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 1987;76(3):534-8.
Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol 1988;62(15):10J-15.
Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for Type 2 diabetes: An update including new drugs and 2-drug combinations. Ann Intern Med 2011;154(9):602-13.
Bennett WL. Oral diabetes medications for adults with Type 2 diabetes: An update. Comparative Effectiveness Review No.27; 2011.
Ravindra BP, Vanishree S, Sujatha S, Kishore KK. Effect of carvedilol on the pharmacokinetics and pharmacodynamics of glipizide. Int J Pharm Pharm Sci 2012;4(3):133-8.
Pandit R, Phadke A, Jagtap A. Antidiabetic effect of Ficus religiosa extract in streptozotocin-induced diabetic rats. J Ethnopharmacol 2010;128(2):462-6.
Barthe L, Bessouet M, Woodley JF, Houin G. The improved everted gut sac: A simple method to study intestinal P-glycoprotein. Int J Pharm 1998;173(1):255-8.
Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969;22(2):158-61.
David Rodrigues A. Drug-Drug Interactions. 2nd ed. USA: Informa Healthcare; 2008.
Wadhwa NK, Schroeder TJ, Pesce AJ, Myre SA, Clardy CW, First MR. Cyclosporine drug interactions: A review. Ther Drug Monit 1987;9(4):399-406.
Whitlock JP, Denison MS. Induction of cytochrome P450 enzymes that metabolize xenobiotics. 2nd ed. New York: Plenum Press; 1995. p. 367-90.
Davidson MH, Lukacsko P, Sun JX, Phillips G, Walters E, Sterman A, et al. A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clin Ther 2002;24(1):112-25.
Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41(5):343-70.
Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: Clinical relevance. Clin Pharmacokinet 2005;44(12):1209-25.
Hansten PD, Horn JR. Cytochrome P450 enzymes and drug interactions, table of cytochrome P450 substrates, inhibitors, inducers and P-glycoprotein, with footnotes. In: The Top 100 Drug Interactions - A guide to Patient Management. Freeland, WA: H&H Publications; 2008. p. 142-57.
Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50(3):209-15.
Sakaeda T, Takara K, Kakumoto M, Ohmoto N, Nakamura T, Iwaki K, et al. Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J Pharm Pharmacol 2002;54(3):419-23.
Bogman K, Peyer AK, Török M, Küsters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001;132(6):1183-92.
Choi DH, Chung JH, Choi JS. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: Role of P-glycoprotein inhibition by lovastatin. Eur J Clin Pharmacol 2010;66(3):285-90.
Hong SP, Yang JS, Han JY, Ha SI, Chung JW, Koh YY, et al. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: Possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol 2011;63(1):129-35.
Makula CS, Reddy PJ. Influence of lovastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits. J Pharm Res 2012;5(4):2018-21.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
